NGL Fine-Chem Ltd to Approve Q2 FY27 Results November 6

NGL Fine-Chem Ltd will consider and approve its unaudited standalone and consolidated Q2 and H1 FY27 results on November 6, 2026, after reporting ₹139 crore in sales and ₹18 crore in net profit for the June 2026 quarter, with profit up 100% year on year.

When will NGL Fine-Chem Ltd announce Q2 FY27 results?

NGL Fine-Chem Ltd has scheduled a Board of Directors meeting for November 6, 2026, to consider and approve unaudited financial results for the quarter and half year ended September 30, 2026. The disclosure was made under Regulation 29(1) of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

The company has also indicated that an earnings conference call to discuss the Q2 and H1 FY27 results is scheduled for November 12, 2026. Its results-related materials for the September quarter are expected to include financial results, an investor presentation, earnings-call transcript and audio, and publication of results.

The announcement is relevant for investors because it will provide the first reported performance update for NGL Fine-Chem after the June quarter. The September-quarter numbers will also show the company’s financial position for the first half of FY27.

What did NGL Fine-Chem Ltd report in the June 2026 quarter?

NGL Fine-Chem Ltd reported sales of ₹139 crore and net profit of ₹18 crore for the quarter ended June 2026. Sales increased 33.7% from ₹104 crore in the corresponding quarter of the previous year, while net profit doubled year on year.

The company’s Board approved the unaudited standalone and consolidated June-quarter results on August 12, 2026. The results were filed along with a limited review report from statutory auditor Manek & Associates.

According to the provided disclosure, the auditor’s review stated that the financial statements were prepared in accordance with Indian Accounting Standard 34 and applicable SEBI requirements. The review did not identify material misstatements in the financial information submitted for the June quarter.

What does NGL Fine-Chem Ltd manufacture?

NGL Fine-Chem Ltd, incorporated in 1981, manufactures and exports pharmaceutical products and intermediates used in veterinary and human health applications. Its primary business is veterinary pharmaceutical active pharmaceutical ingredients, or APIs, and intermediates serving antiprotozoal and anthelmintic therapeutic segments.

The company’s products are used in the animal healthcare industry. Its disclosed portfolio includes about 39 APIs, comprising 37 veterinary APIs and two human APIs, around four intermediates, and about 12 finished dosage forms. The portfolio covers categories such as anthelmintics, antiprotozoals, ectoparasiticides and phosphorus supplements.

This product mix is important when assessing quarterly results because the company serves specialised pharmaceutical markets rather than a broad consumer-products market. Revenue performance can therefore be viewed in the context of its veterinary API and formulation operations, although the company has not yet disclosed the September-quarter financial figures.

How will the November 6 meeting matter for investors?

The November 6 meeting matters because NGL Fine-Chem will disclose its unaudited September-quarter and first-half FY27 financial performance. Investors will be able to compare the figures with the ₹139 crore sales and ₹18 crore net profit reported for the June 2026 quarter.

The company has stated that its trading window was closed from October 1 ahead of the results process. Such a closure restricts trading by designated persons during the period governed by the company’s internal code and applicable listing regulations.

The scheduled November 12 earnings call provides a further event for investors seeking management commentary on the reported quarter. The supplied information does not disclose any forecast, guidance, margin target, capex plan, or operational target for Q2 or the full financial year. Therefore, the November disclosures will be the next source of confirmed information on performance and management discussion.

How has NGL Fine-Chem’s quarterly sales trend developed?

NGL Fine-Chem’s reported quarterly sales figures in the supplied historical table show an increase from ₹88 crore in June 2024 to ₹101 crore in June 2025 and ₹137 crore in June 2026. Separately, the June 2026 results summary states sales of ₹139 crore. The company’s formal June-quarter result disclosure should be used as the relevant reference for the reported quarterly result.

The historical table also shows sales of ₹145 crore for the quarter ended March 2026. The September 2026 results, once approved and published, will add the next data point for assessing the company’s reported revenue pattern during FY27.

Conclusion

NGL Fine-Chem is due to approve its Q2 and H1 FY27 unaudited results on November 6, following a June quarter in which it reported ₹139 crore of sales and ₹18 crore of net profit. The disclosed year-on-year growth in sales and profit provides the confirmed financial context ahead of the September-quarter update.

The next scheduled disclosures are the Board’s November 6 results decision and the November 12 earnings conference call. Investors will watch for the reported September-quarter and first-half financial figures, as well as any management commentary contained in the results materials and call.